COLL

Collegium Pharmaceutical, Inc. [COLL] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

COLL Stock Summary

Top 10 Correlated ETFs

COLL

Top 10 Correlated Stocks

COLL

In the News

COLL Financial details

Company Rating
-
Market Cap
1.14B
Income
48.16M
Revenue
566.77M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
197
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
120.81
Forward P/E
-
PEG
-4.05
P/S
1.93
P/B
6.09
P/C
-
P/FCF
3.95
Quick Ratio
1.05
Current Ratio
1.16
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
1.47
EPS next Y
-
EPS next Q
-
EPS this Y
-293.24%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
13.82%
Revenue Q/Q
9.54%
EPS Q/Q
62.3%
-
-
-
-
SMA20
3.33%
SMA50
6.9%
SMA100
6.9%
Inst Own
-
Inst Trans
-
ROA
1%
ROE
5%
ROC
0.11%
Gross Margin
51%
Oper. Margin
14%
Profit Margin
2%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
20.83-40.95
52W High
-23.38%
52W Low
+53.25%
RSI
47
Rel Volume
0.29
Avg Volume
409.13K
Volume
118.57K
Perf Week
-3.13%
Perf Month
4.11%
Perf Quarter
-0.97%
Perf Half Y
-9.61%
-
-
-
-
Beta
1.045
-
-
Volatility
0.56%, 1.03%
Prev Close
-1.79%
Price
30.65
Change
-2.23%

Something similar

Top by Market Cap
TL0.DE
MSFT
BRK-B
DHR-PB
FXAIX
Top Correlated ETFs
XBI
LABU
KV4.SI
BBP
PBE
Top Correlated Stocks
TH
RAIL
0QZU.L
GTN
VRTX
Similar Market Cap
TA
SALSTEEL.NS
MITK
LSAQ
CNXN

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic
  • Volume Average 409.13K
  • Market Capitalization 1.14B
  • Employee 197
  • CEO Mr. Joseph J. Ciaffoni
  • Headquarters Stoughton,MA,US
  • IPO Date 2015-05-07
  • Website https://www.collegiumpharma.com

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.